SciSparc Issued U.S. Patent For Its Core Technology That Treats Central Nervous Systems Disorders
January 4, 2022
Patent Extends Protection for its Novel Compounds and Methods Already granted in Australia and Japan TEL AVIV, Israel, Jan. 4, 2022 /PRNewswire/ — SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company” or “SciSparc”), marks... Read more
